This meta-analysis aimed to assess the efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.